Resveratrol, through NF‐Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38MAPK/CK2 signaling in human breast cancer cells
暂无分享,去创建一个
S. Fuqua | S. Andò | M. Pellegrino | A. Vivacqua | F. Giordano | Francesca De Amicis | Francesca Giordano | Adele Vivacqua | Michele Pellegrino | Maria Luisa Panno | Donatella Tramontano | Suzanne A W Fuqua | Sebastiano Andò | F. De Amicis | D. Tramontano | M. L. Panno | S. Fuqua
[1] B. Vogelstein,et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.
[2] K. Matsumoto,et al. Phosphorylation of the retinoblastoma protein by cdk2. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[3] R. Sutherland,et al. Circumvention of tamoxifen resistance by the pure anti‐estrogen ICI 182, 780 , 1993, International journal of cancer.
[4] R. Lupu,et al. Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells , 1995, International journal of cancer.
[5] Daniel Metzger,et al. Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.
[6] D. Picard,et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.
[7] R. Hansen,et al. Auto-regulation of the estrogen receptor promoter , 1997, The Journal of Steroid Biochemistry and Molecular Biology.
[8] E. Surmacz,et al. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. , 1997, Cancer research.
[9] M. Sporn,et al. Recent advances in chemoprevention of cancer. , 1997, Science.
[10] S. Cheng,et al. The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. , 1997, Biochemical and biophysical research communications.
[11] B. O’Malley,et al. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.
[12] M. Fontecave,et al. Resveratrol, a remarkable inhibitor of ribonucleotide reductase , 1998, FEBS letters.
[13] H. Ciolino,et al. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. , 1999, Molecular pharmacology.
[14] G. Condorelli,et al. The B Subunit of the CAAT-binding Factor NFY Binds the Central Segment of the Co-activator p300* , 1999, The Journal of Biological Chemistry.
[15] Z. Darżynkiewicz,et al. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. , 1999, International journal of oncology.
[16] G. Liu,et al. p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. , 1999, Biochemical and biophysical research communications.
[17] J. Pezzuto,et al. Cancer Chemopreventive Activity of Resveratrol , 2002, Drugs under experimental and clinical research.
[18] Jen-kun Lin,et al. Suppression of nitric oxide synthase and the down‐regulation of the activation of NFκB in macrophages by resveratrol , 1999, British journal of pharmacology.
[19] Weiya Ma,et al. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. , 1999, Carcinogenesis.
[20] Jianbiao Zheng,et al. Inhibition of mitochondrial proton F0F1‐ATPase/ATP synthase by polyphenolic phytochemicals , 2000, British journal of pharmacology.
[21] C. Klinge,et al. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. , 2000, Endocrinology.
[22] C. Klinge,et al. Printed in U.S.A. Copyright © 2000 by The Endocrine Society Resveratrol Acts as a Mixed Agonist/Antagonist for , 2022 .
[23] K. Christman,et al. Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. , 2000, Biochemical pharmacology.
[24] Kristen Jepsen,et al. Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development , 2000, Cell.
[25] M. Murphy,et al. The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation , 2001, Molecular and Cellular Biology.
[26] J. Reiffers,et al. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. , 2002, Carcinogenesis.
[27] S. Hilsenbeck,et al. Sp1 is essential for estrogen receptor alpha gene transcription. , 2002, The Journal of steroid biochemistry and molecular biology.
[28] S. Hilsenbeck,et al. Sp1 is essential for estrogen receptor α gene transcription , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[29] Patrick Diel,et al. Tissue-specific estrogenic response and molecular mechanisms. , 2002, Toxicology letters.
[30] S. Benchimol,et al. Transcriptional repression mediated by the p53 tumour suppressor , 2003, Cell Death and Differentiation.
[31] L. Donehower,et al. Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. , 2003, Mutation research.
[32] F. Scarlatti,et al. The FASEB Journal express article 10.1096/fj.03-0292fje. Published online October 16, 2003. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling , 2022 .
[33] R. Nicholson,et al. Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells , 2003, Breast Cancer Research and Treatment.
[34] E. Diamandis,et al. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer , 2004, Breast Cancer Research and Treatment.
[35] W. McGuire,et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen , 2004, Breast Cancer Research and Treatment.
[36] C. Kedinger,et al. A p38 inhibitor allows to dissociate differentiation and apoptotic processes triggered upon LIF withdrawal in mouse embryonic stem cells , 2004, Cell Death and Differentiation.
[37] Bert W O'Malley,et al. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. , 2004, Endocrine reviews.
[38] A. Fornace,et al. Casein Kinase 2- and Protein Kinase A-regulated Adenomatous Polyposis Coli and β-Catenin Cellular Localization Is Dependent on p38 MAPK* , 2005, Journal of Biological Chemistry.
[39] L. Chodosh,et al. Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. , 2005, Cancer research.
[40] A. Gartel,et al. Lost in transcription: p21 repression, mechanisms, and consequences. , 2005, Cancer research.
[41] R. Mantovani,et al. Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters , 2005, Molecular and Cellular Biology.
[42] R. Kumar,et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. , 2005, Endocrine-related cancer.
[43] Hung-Yun Lin,et al. Integrin αVβ3 contains a receptor site for resveratrol , 2006 .
[44] S. Hilsenbeck,et al. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. , 2006, Cancer research.
[45] Hung-Yun Lin,et al. Integrin alphaVbeta3 contains a receptor site for resveratrol. , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] C. Prives,et al. Transcriptional regulation by p53: one protein, many possibilities , 2006, Cell Death and Differentiation.
[47] J. Davie,et al. Differential Distribution of Unmodified and Phosphorylated Histone Deacetylase 2 in Chromatin* , 2007, Journal of Biological Chemistry.
[48] M. Cammer,et al. Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. , 2007, Neoplasia.
[49] G. Sauter,et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.
[50] B. O’Malley,et al. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] L. Donehower,et al. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity , 2007, Mechanisms of Ageing and Development.
[52] I. Morita,et al. Protein kinase CK2 is a key activator of histone deacetylase in hypoxia‐associated tumors , 2008, International journal of cancer.
[53] S. Andò,et al. Evidence that bergapten, independently of its photoactivation, enhances p53 gene expression and induces apoptosis in human breast cancer cells. , 2009, Current cancer drug targets.
[54] Jie Tian,et al. Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. , 2009, Cancer research.
[55] S. Fuqua,et al. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305 , 2009, Breast Cancer Research and Treatment.
[56] S. Fuqua,et al. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. , 2009, Molecular endocrinology.
[57] I. Barone,et al. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter. , 2009, Molecular endocrinology.
[58] D. Das,et al. Dose-Dependency of Resveratrol in Providing Health Benefits , 2010, Dose-response : a publication of International Hormesis Society.